France: Juvisé Pharmaceuticals refinances funding raised to acquire rights to Pylera

French specialty pharmaceutical company, Juvisé Pharmaceuticals, has completed a €400m (US$405.5m) refinancing following the acquisition of the worldwide rights to Pylera, an antimicrobial tri-therapy indicated for gastro-intestinal Helicobacter pylori infections from US-based AbbVie. Pylera is a 3-in-1 combination of antimicrobial products, and is indicated for the treatment of patients with Helicobacter pylori infection suffering from…

You must be a HMI Subscriber to view this content.

Subscribe Now »